🗂️
Archived grant — no longer open
This grant has closed and is kept as a historical reference. Browse current grants for active opportunities.
grant
Medication Development for the Treatment of Alcohol Use Disorder
Organization TEXAS TECH UNIVERSITY HEALTH SCIS CENTERLocation LUBBOCK, UNITED STATESPosted 20 Dec 2024Deadline 31 Aug 2025 ⚠️
NIHUS FederalResearch GrantFY20254-Nitrophenol-2-HydroxylaseABC15ABC20ABCB1ABCB1 geneABCG2ABCG2 geneABCPATP-Binding Cassette, Sub-Family G (WHITE), Member 2 GeneATP-Binding Cassette, Sub-Family G, Member 2ATP-Binding Cassette, Subfamily G, Member 2Abnormal Assessment of MetabolismAbsolute ethanolAddressAromatic Compound-Inducible Cytochrome P-450BCRPBCRP1BindingBinding ProteinsBloodBlood PlasmaBlood Reticuloendothelial SystemBlood erythrocyteBreast Cancer Resistance ProteinCP12CP34CPE1CYP 1A2CYP 2E1CYP IIE1CYP1A2CYP1A2 geneCYP2B6CYP2B6 geneCYP2ECYP2E1CYP2E1 geneCYP3CYP3ACYP3A4CYP3A4 geneCYPE1CYPIIE1Caffeine DemethylaseCanine SpeciesCanis familiarisChemistryClinical ResearchClinical StudyClinical TreatmentCollaborationsCommon Rat StrainsComplexCryofixationCryopreservationCytochrome P-450Cytochrome P-450 CYP1A2Cytochrome P-450 CYP2E1Cytochrome P-450 Enzyme SystemCytochrome P-450 IIE1Cytochrome P-450 LM4Cytochrome P-450-JCytochrome P-450dCytochrome P450Cytochrome P450 1A2Cytochrome P450 2E1Cytochrome P450 3A4Cytochrome P450 Family GeneCytochrome P450, Family 2, Subfamily E, Polypeptide 1Cytochrome P450, Phenobarbital-InducibleCytochrome P450, Subfamily IIB, Polypeptide 6Cytochrome P450, Subfamily IIIA, Polypeptide 4Cytochrome P450, subfamily Ethanol-Inducible, Polypeptide 1Cytochrome P450PCN1Cytochrome aDSM-5DSM-VDSM5DangerousnessDevelopmentDiagnostic and Statistical Manual of Mental Disorders, 5th editionDiagnostic and Statistical Manual of Mental Disorders-VDialysisDialysis procedureDimethylnitrosamine N-DemethylaseDioxin-Inducible P3-450DiseaseDisorderDogsDogs MammalsDoseDrug InteractionsDrug TherapyDrugsEST157481ETOHEarly-Stage Clinical TrialsEnzyme GeneEnzymesEquilibriumErythrocytesErythrocyticEthanolEthanol-Inducible P450EthersEthyl AlcoholExcretory functionFAMILY III P450FDA approvedFoundationsFundingGP170Gene ExpressionGlucocorticoid-Inducible P450GoalsGrain AlcoholHepatic CellsHepatic Parenchymal CellHepatocyteHumanIND FilingIND applicationIND packageIND submissionIn VitroIndividualInnate Immune SystemIntermediary MetabolismInvestigational New Drug ApplicationIsoenzymesIsozymesLaboratoriesLeadLigand Binding ProteinLigand Binding Protein GeneLiver CellsLiver MicrosomesMDR-1MDR1MDR1 ProteinMRXMXR1Marrow erythrocyteMedicalMedicationMetabolicMetabolic ProcessesMetabolic StudiesMetabolismMetabolism StudiesMethylcarbinolMiceMice MammalsMinocyclineMitoxantrone Resistance ProteinModern ManMolecular InteractionMorbidityMorbidity - disease rateMultidrug Resistance 1Multidrug Resistance Gene-1Multidrug Resistance Gene-1sMultidrug Resistance ProteinsMultidrug Resistant ProteinsMurineMusN-Nitrosodimethylamine DemethylaseNIAAANational Institute on Alcohol Abuse and AlcoholismNifedipine OxidaseP(3)450P-GPP-GlycoproteinP-Glycoprotein 1 GeneP3-450P450P450 4P450 Form 4P450 orm 4P450-2E1P450-JP450-P3P450C2EP450C3P450PCN1PGY-1 ProteinPGY1PatientsPb elementPersonsPharmaceutical PreparationsPharmacological TreatmentPharmacotherapyPhase 1 Clinical TrialsPhase I Clinical TrialsPhenacetin O-DealkylasePhenotypePhysical DependencePlacenta-Specific ATP-Binding Cassette TransporterPlasmaPlasma ProteinsPlasma SerumProtein BindingRatRats MammalsRattusReactionRed Blood CellsRed CellResearchRestReticuloendothelial System, Serum, PlasmaRiskSafetySteroid-Inducible P450- IIISubfamily Ethanol-Inducible Cytochrome P450Subfamily IIE Cytochrome P450TimeTransportationWhole BloodWithdrawal Symptomalcohol use disorderat-risk drinkingbalancebalance functionblood corpusclesbound proteincanineclinical interventionclinical therapycold preservationcold storagedevelop therapydevelopmentaldialysis therapydomestic dogdrug interventiondrug treatmentdrug/agentethanol use disorderexcretionfirst in manfirst-in-humanheavy metal Pbheavy metal leadhigh risk drinkinghuman studyindexingintervention developmentmanufacturemetabolic abnormality assessmentoff-label applicationoff-label prescribingoff-label usepharmaceutical interventionpharmacological interventionpharmacological therapypharmacology interventionpharmacology treatmentpharmacotherapeuticsphase I protocolpre-clinicalpreclinicalpublic health relevancerisky drinkingsafety testingsuccesstherapy developmenttreatment developmenttrial regimentrial treatment
Applications closed.
Description preview
Nearly 15 million people in the US and ~100 million worldwide suffer from AUD. Over 5% of all medical
morbidities share an ethanol-related risk. Although there are three FDA approved drugs to treat AUD, and several
others are used off-label, medications have shown only modest success (~20%) in the treatment of patients.
Consequently, there is an…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click